]>
IRCT20230723058900N1 IRCT 2023-10-19 Rasht University of Medical Sciences Investigating the effect of magnesium supplementation on cardiorenal syndrome Investigating the effect of magnesium oxide supplementation on the quality of life of patients with cardiorenal syndrome caused by chronic heart failure with reduced ejection - A single-arm clinical trials 2023-11-06 anticipated 30 Complete https://irct.ir/trial/71947 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Supportive. 2 Heart failure. Intervention group: Giving 250 mg magnesium oxide supplements by jalinous Pharmaceutical Company for 3 months with a gap of one day between drug doses.. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is The professors have not made a decision yet
public Samira Arami
Cardiovascular Diseases Research Center- Dr. Heshmat Heart Center - next to Gilan Province Management and Planning Organization - 15 Khordad St. -Rasht
Rasht Iran (Islamic Republic of) 4193955588 +98 13 3361 8177 samira523@yahoo.com Rasht University of Medical Sciences scientific Samira Arami
Cardiovascular Diseases Research Center- Dr. Heshmat Heart Center - next to Gilan Province Management and Planning Organization - 15 Khordad St. -Rasht
Rasht Iran (Islamic Republic of) 4193955588 +98 13 3361 8177 samira523@yahoo.com Rasht University of Medical Sciences Iran (Islamic Republic of) Age over 18 years Outpatients referred to the clinic diagnosed with chronic heart failure (ECO result with EF less than 40%) Patients with renal failure or evidence of renal damage (decrease in GFR below normal for more than 3 months or albuminuria above 30 mg/dl in 24-hour urine) GFR more than 30 mL/min Serum magnesium below 2 mg/dl 18 years no limit Both Current treatment with hemodialysis or peritoneal dialysis Donated kidney recipient or kidney donor Coronary artery bypass grafting Previous parathyroidectomy Hyperparathyroidism Current treatment with medication or supplements containing magnesium (antacids) Recent history of treatment with medicine or supplements containing magnesium Any condition that interferes with the absorption of magnesium from the digestive system (short bowel syndrome / chronic pancreatitis) Pregnant mothers, mothers during breastfeeding Allergy to the contents of the medicine Patient participation in other intervention trials Hypothyroidism and hyperthyroidism Patients showing features of other primary kidney diseases Urinary tract infection Any fever associated with infection Active malignancies Liver cirrhosis and chronic alcoholism All people who used cigarettes and other tobacco products ESRD and stage five CKD Laxatives and other nephrotoxic drugs I50.9 Heart failure, unspecified Treatment - Drugs Intervention group: Giving 250 mg magnesium oxide supplements by jalinous Pharmaceutical Company for 3 months with a gap of one day between drug doses. Score of patients in the Kansas City Cardiomyopathy Questionnaire (KCCQ12). Timepoint: Completing the questionnaire at the beginning of the trial and 3 months after taking the magnesium oxide supplement. Method of measurement: Kansas City Cardiomyopathy Questionnaire. Measuring patients' performance in the 6-minute walking test. Timepoint: Measuring patients' performance at the beginning of the trial and 3 months after magnesium oxide supplementation. Method of measurement: 6-minute walking test. Rasht University of Medical Sciences Approved 2023-06-28 Research Ethics Committees of Guilan university of medical sciences Cardiovascular Diseases Research Center- Dr. Heshmat Heart Center - next to Gilan Province Management and Planning Organization - 15 Khordad St. -Rasht Rasht Guilan Iran (Islamic Republic of)